More participants in the higher-dose group than placebo achieved an HbA1c under 7% (55.9% vs 15.2%) or under 6.5% (29.4% vs 6 ...

Hospital-based care for hallucinogen use is associated with increased mortality, according to a study published online March ...

The company reported a Q4 EPS of $0.15, which was $0.07 higher than the analyst estimate of $0.08. Revenue for the quarter came in at $108.19 million, outpacing the consensus estimate of $97.66 ...

Simultaneous expansion and activation of both major γδ T cell subsets (Vδ1+ and Vδ2+) leverages both the rapid antigen ...

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. ), and Arbutus ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to ...

SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO ...

LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following inve ...